In a phase I/II study, combination therapy of sorafenib with cytarabine and idarubicin in treatment-naive AML patients under 65 years, 83% of FLT3 wild-type patients and 95% of FLT3 mutant patients showed a CR or PR [160]. This evidence concerns the gene FLT3 and acute myeloid leukemia.